Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1631708 | 1.00 | HSD17B10 (0.56) | HSD17B10SMN1; SMN2RAB9ANPC1CHRM2 | |
| SCHEMBL73359 | 1.00 | HSD17B10 (0.56) | HSD17B10SMN1; SMN2RAB9ANPC1CHRM2 | |
| SCHEMBL27877016 | 0.89 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL85536 | 0.89 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL6219872 | 0.89 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL67045 | 0.89 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL67044 | 0.89 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL20690006 | 0.89 | HSD17B10 (0.50) | HSD17B10SMN1; SMN2RAB9ANPC1CHRM2 | |
| SCHEMBL18554450 | 0.89 | HSD17B10 (0.50) | HSD17B10SMN1; SMN2RAB9ANPC1CHRM2 | |
| SCHEMBL65490 | 0.88 | HSD17B10 (0.63) | HSD17B10SMN1; SMN2RAB9ANPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 625 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026087442-A1 | AMINO-IMIDAZOLE ANTIBACTERIAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260076968-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2026-03-19 | — | — | US | disclosed |
| EP-4709712-A1 | GSK3A INHIBITORS AND METHODS OF USE THEREOF | Blueprint Medicines Corporation (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4034535-B1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2026-03-04 | — | — | EP | disclosed |
| US-12565494-B2 | Inhibitors of human respiratory syncytial virus and metapneumovirus | MERCK SHARP & DOHME LLC | 2026-03-03 | — | — | US | disclosed |
| US-20260049054-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA AS (DK) | 2026-02-19 | — | — | US | disclosed |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-02-12 | — | — | US | disclosed |
| US-12544374-B2 | AZA-quinoline compounds and uses thereof | NOVARTIS AG (CH) | 2026-02-10 | — | — | US | disclosed |
| US-5416093-A | DIPEPTIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1995-05-16 | — | — | US | disclosed |
| US-5409946-A | Antiepileptic agent | ABBOTT LABORATORIES (US) | 1995-04-25 | — | — | US | disclosed |
| EP-0574174-A2 | Angiotensin II antagonists | ELI LILLY AND COMPANY (US) | 1993-12-15 | — | — | EP | disclosed |
| US-5252566-A | Antithrombotic agents | ELI LILLY AND COMPANY (US) | 1993-10-12 | — | — | US | disclosed |
| US-5250517-A | Hypotensive and cardiotonic agents; cardiac insufficiency | HOFFMANN-LA ROCHE INC. (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0542525-A2 | Antithrombotic agents | ELI LILLY AND COMPANY (US) | 1993-05-19 | — | — | EP | disclosed |
| US-4902684-A | Benzazepine and benzothiazepine derivatives | E. R. SQUIBB & SONS, INC. (US) | 1990-02-20 | — | — | US | disclosed |
| WO-1989012633-A1 | BENZAZEPINE AND BENZOTHIAZEPINE DERIVATIVES | E.R. SQUIBB & SONS, INC. (US) | 1989-12-28 | — | — | WO | disclosed |
| US-4576749-A | 3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones | E. R. SQUIBB & SONS, INC. (US) | 1986-03-18 | — | — | US | disclosed |
| EP-0138407-A1 | Azetidinones | E.R. Squibb & Sons, Inc. (US) | 1985-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | IL6ST, GFRA3, GFRA1 | HSD17B10 342/4885SMN1; SMN2 36/4885RAB9A 893/4885 |
| US-20260076968-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | EZH2, SUZ12, NR3C1 | HSD17B10 565/4885SMN1; SMN2 492/4885RAB9A 1904/4885 |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | GFRA3, IL6ST, GFRA1 | HSD17B10 323/4885SMN1; SMN2 37/4885RAB9A 914/4885 |
| US-12544374-B2 | AZA-quinoline compounds and uses thereof | EZH2, NR3C1, SUZ12 | HSD17B10 674/4885SMN1; SMN2 1004/4885RAB9A 1550/4885 |
| US-20260049054-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SCN10A, KCNK10, KCNJ2 | HSD17B10 1259/4885SMN1; SMN2 3226/4885RAB9A 490/4885 |
| US-12565494-B2 | Inhibitors of human respiratory syncytial virus and metapneumovirus | NHERF1, ZC3HAV1, SARS1 | HSD17B10 2820/4885SMN1; SMN2 344/4885RAB9A 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.